Craft

Elanco

Stock Price

$16.8

2024-05-24

Market Capitalization

$8.3 B

2024-05-24

Revenue

$4.4 B

FY, 2023

Elanco Summary

Company Summary

Overview
Elanco is a company that develops, manufactures, and delivers products to prevent and treat disease in farm animals and pets. It offers vaccines, nutritional enzymes, antibiotics, parasiticides, and other products.
Type
Public
Status
Active
Founded
1954
HQ
Greenfield, IN, US | view all locations
Website
https://www.elanco.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Jeffrey N. Simmons

    Jeffrey N. Simmons, President, CEO & Director

  • Ramiro Cabral

    Ramiro Cabral, Executive Vice President, Elanco International

  • Fadi Debes

    Fadi Debes, Senior Vice President, Corporate Controller and Financial Services

  • Dave Kinard

    Dave Kinard, Executive Vice President, Human Resources, Corporate Affairs & Administration

Operating MetricsView all

Brands

200
5.3%

Q3, 2022

Countries

90

Q3, 2022

Sales Representatives

2.1K
6.3%

FY, 2021

LocationsView all

40 locations detected

  • Greenfield, IN HQ

    United States

    2500 Innovation Way/2710 Innovation Way

  • Buenos Aires, Provincia de Buenos Aires

    Argentina

    Colectora Este Ramal Pilar Manuel Alberti Suite 317

  • Macquarie Park, NSW

    Australia

    7 Eden Park Dr

  • Wien, Wien

    Austria

    Quartier Belvedere Central, Gertrude-Fröhlich-Sandner-Straße 3

  • Antwerpen, Vlaams Gewest

    Belgium

    Plantin en Moretuslei 1A

  • São Paulo, SP

    Brazil

    Av. das Nações Unidas, 14401, Torre Jequitibá

and 34 others

Elanco Financials

Summary Financials

Revenue (Q1, 2024)
$1.2B
Gross profit (Q1, 2024)
$690.0M
Net income (Q1, 2024)
$32.0M
Cash (Q1, 2024)
$345.0M
Enterprise value
$13.7B

Footer menu